Bisphosphonates in prostate cancer: Where are we and where should we go?

Journal of the National Cancer Institute

Volumn 95, Issue 17, 2003, Pages 1262-1263

  Saad, Fred ^a  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; PAMIDRONIC ACID; PLACEBO; ZOLEDRONIC ACID; ANTIANDROGEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; IMIDAZOLE DERIVATIVE; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; BONE METASTASIS; BONE TURNOVER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CASTRATION; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; MALE; OSTEOLYSIS; PRIORITY JOURNAL; PROSTATE CANCER; BONE TUMOR; CHEMICALLY INDUCED DISORDER; CONTROLLED CLINICAL TRIAL; INTRAVENOUS DRUG ADMINISTRATION; METASTASIS; NEOPLASM; NOTE; ORAL DRUG ADMINISTRATION; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PATHOLOGY; PROSTATE TUMOR; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; CLODRONIC ACID; DIPHOSPHONATES; FRACTURES, SPONTANEOUS; HUMANS; IMIDAZOLES; INFUSIONS, INTRAVENOUS; MALE; NEOPLASMS, HORMONE-DEPENDENT; OSTEOPOROSIS; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0042331517     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/djg062     Document Type: Editorial

References (9)

1. Smith MR. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer 2003;97(3 Suppl):789-95.
2. Bisphosphonates for osteoporosis. Drug Ther Bull 2001;39:68-72.
3. Smith MR, Eastham J, Gleason DM, Shasha D, Tchekmedyian S, Zinner N, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. J Urol 2003;169:2008-12.
4. Body JJ. Effectiveness and cost of bisphosphonate therapy in tumor bone disease. Cancer 2003;97(3 Suppl):859-65.
5. Lipton A, Small E, Saad F, Gleason D, Gordon D, Smith M, et al. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest 2002;20(Suppl 2):45-54.
6. Saad F. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid. Semin Oncol 2002;29(6 Suppl 21):19-27.
7. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94:1458-68.
8. Dearnaley DP, Sydes MR, Mason MD, Stott M, Powell CS, Robinson AC, et al. A double-blind, placebo-controlled, randomized trial of sodium clodronate for metastatic prostate cancer (MRC PR05 trial). J Natl Cancer Inst 2003;95:1300-11.
9. Ernst DS, Tannock IF, Venner PM, Winquist EW, Reyno L, Walker H, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPc) and pain: National Cancer Institute of Canada Clinical Trials Group study [abstract]. Proc ASCO 2002;21:177a.